Ischaemic preconditioning and stem cell mobilisation
نویسندگان
چکیده
منابع مشابه
Ischaemic preconditioning and stem cell mobilisation.
Ischaemic preconditioning (IPC) (1) refers to repeated brief episodes of ischaemia, which itself does not result in cells death, protects the myocardium from a subsequent ischaemic insult. A better understanding of the mechanism of this cardioprotective effect could potentially lead to the development of novel therapeutics that can be used in the clinical setting. Previous studies (2) have been...
متن کاملCytoprotection and Preconditioning for Stem Cell Therapy
Coronary heart disease is the leading cause of morbidity and mortality worldwide. To date, management of myocardial infarction (MI) has been limited to timely revascularization and drug therapy aimed to restore coronary blood flow and to reduce myocardial workload. When disease progresses to life-threatening end-stage heart failure, heart transplantation is the only effective therapeutic option...
متن کاملCardioprotection by remote ischaemic preconditioning.
Perioperative myocardial infarction is a leading cause of morbidity and mortality after major non-cardiac surgery. Pharmacological agents such as beta-blockers may reduce the risk but are associated with side-effects and may be contra-indicated in some patients. Basic scientific experiments and preliminary clinical trials in humans suggest that remote ischaemic preconditioning (RIPC), where bri...
متن کاملIschaemic preconditioning: present position and future directions.
Preconditioning the myocardium using short episodes of sublethal ischaemia will delay the onset of necrosis during a subsequent lethal ischaemic insult. This powerful protective adaptation of the myocyte has also been observed in other cell types. The potential for clinical application to benefit patients with a variety of pathological conditions has led to an expansion in our knowledge concern...
متن کاملPlerixafor for Stem Cell mobilisation prior to BMT
The drug and the review Plerixafor was licensed in the UK in August 2009 to be used in combination with G-CSF to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly. The recommended dose of plerixafor is 0.24mg/kg body weight per day (to a max...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Thrombosis and Haemostasis
سال: 2010
ISSN: 0340-6245,2567-689X
DOI: 10.1160/th09-12-0839